At Linker Sciences, we are industry-focused scientists with deep expertise in mass spectrometry and drug discovery who identified a critical gap in early therapeutic development unattainable through DNA-encoded library (DEL) technologies and structure-based drug design (SBDD) methods including computer-aided drug discovery (CADD) and AI-driven drug design (AIDD). We are building a platform that integrates high-resolution mass spectrometry with AI-driven analytics to generate next-generation drug libraries of small molecules, short peptides and non-canonical chemistries. Our technology enables the discovery of bioactive scaffolds from underexplored chemical space to open new frontiers in drug discovery and development.

Mass spectrometry instruments are reaching a critical point in resolution and sensitivity which can pose them as the most advanced analytical tool for drug screening. Embracing these advancements, we are building a technology that enables direct and precise measurement of molecular interactions to provide biological insights that other technologies cannot.

At Linker Sciences, we integrate mass spectrometry advancements into SDP (Spectra Decoding Platform) technology to access chemical space previously seemed inaccessible. Our technology aims to accelerate the discovery of novel therapeutics while opening new market opportunities within the drug discovery sector.